Jury

JoomFish-Language Selection

Find us on :

Jury composition of Innovation Prize 2012 will be available soon

Jury 2011

The jury of Innovation Prize will be chaired by Jean Deregnaucourt (Institut Pasteur) and made up of European representatives from Institutional experts & industrial partners.

Jean Deregnaucourt – Institut Pasteur

D V M, Thesis Prize Winner, Graduate in Pharmacology (Paris Medical Faculty), Post doctoral fellow at University of California at Los Angeles (USA), is currently Vice President Executive Vice President Business Development at Institut Pasteur. Previously, he was Vice President Business and President Advisor at Pierre Fabre Laboratories. As such, he is involved in strategic projects like establishing partnerships and developments in China. He is also Vice President of the Biotech company Cellvir which he cofounded 2 years ago. His previous positions were Vice President Global Project Management then, Vice President Global Chemical and Pharmaceutical Development at Rhone Poulenc Rorer, now known as Sanofi- Aventis (1990-1998) and, lately, President of the Pierre Fabre Research Institute (1998-2003). Thirty years in the pharmaceutical Industry at positions of growing responsibilities gave him the opportunity to know of many projects and to acquire a broad expertise in all aspects of the pharmaceutical R&D process. As such, Jean Deregnaucourt contributed to the development and the international registration of a dozen of international products among them two blockbusters, namely, Clexane and Taxotere. He then moved to an institutional position as Director Biotechnology at the French Research Ministry (2003-2006). In this later position Jean Deregnaucourt seated on the board of the Institut National de la Recherche Medicale (Inserm), of the Institut National de la Recherche Agronomique (INRA) and of the Institut National du Cancer (InCa) among other Institutes. He was also a member of the Haute Autorité de Santé (HAS) and of the Comité Economique des Produits de Santé (CEPS) and contributed also in establishing a European Network for public-private partnerships. Through is dual career path, Jean Deregnaucourt benefited from the unique opportunity to gain exposure of both the private and the public sectors and built a large expertise in the health field.
r path, Jean Derégnaucourt benefited from the unique opportunity to gain exposure of both the private and the public sectors and built a large expertise in the health field.

Stéphane HOGAN – European Commission

Stéphane Hogan is currently Head of the Coordination Unit in the Health Directorate of DG Research. His unit is responsible for planning and coordination of the Health research programme in the EC’s 7th Framework programme, which foresees €6.1 billion in grants for Health research over the period 2007-2013. His unit is also responsible for crosscutting issues such as industry participation, international
cooperation, ethics and communication. Prior to that he spent several years in research in Ireland and Belgium, then worked in journalism and in corporate communications in France, before joining the European Commission (DG Research) in Brussels in 1996. Stéphane holds a degree in science (Genetics) and an MSc in Biotechnology from Trinity College Dublin (Ireland), as well as an MBA from The Open University (UK).

Manfred HORST – MSD

Dr. Manfred Horst is Director, Licensing & External Research Europe, at Merck & Co. He is based at Merck’s French affiliate Laboratoires MSD Chibret in Paris and searches for Licensing opportunities and scientific partnerships across all therapeutic areas in a number of European countries.
Manfred studied medicine in Munich, Montpellier and London and specialised in Allergic Diseases at the University Clinic in Montpellier. After his MBA at INSEAD, Fontainebleau, he started a career in the life sciences industry: 7 years with Ciba-Geigy and Novartis in Basel, 2 years in the health insurance business with an affiliate of Munich Re in Munich, and now 10 years with Merck & Co./MSD in both Munich and Paris. In his current function as since October 2004, Manfred has been instrumental in a number of recent Merck deals - e.g. with Pierre Fabre, Nicox, Morphosys.

Antony LEBEAU – ANR

PhD in Neuropharmacology (University Paris Descartes) and titular of a Master’s degree in Company Management (CNAM-International Institut of Management), Antony Lebeau has successively worked as a research engineer (Inserm/Research Institut of Servier), a project manager (GIS Prion-Ministry of Research), a project manager/communication manager (Inserm-Tranfert and Inserm-Transfert Initiative, participation for the organization of tremplins Entreprises-Sénat).He joined the French National Research Agency (ANR) as a project manager for the department of “Heath Biology”, in charge of RIB/Biotecs and TecSan programs. He currently works in the ANR department of “Promising Investments” in charge of requests of proposal “Technological Institute Research” and “Institutes of Excellence” on decabornylated energies. Antony Lebeau is also expert for the European Commission and for the ERC in the fields of “Health and Biotechnology” and “Ethic and Governance”.

Bernard PAU – Research Ministry

Bernard Pau is a chemical engineer (Ecole Nationale Superieure de Chimie de Montpellier). He holds a doctorate in biochemistry (Universite des Sciences et Techniques du Languedoc, Montpellier) and attended the Institut Pasteur (Paris). He also earned a doctorate in immunology (Montpellier) and an aggregation in pharmaceutical sciences (Paris).
After beginning his career in 1975 in industry (Coulter Group) and then contributing to the development of immunological research at the Sanofi Group, Bernard Pau took up a university post in 1983. Since then, he has combined teaching, training, innovative research, and partnerships for economic development. Since 1992, he has led the "Immunoanalyse et Innovation en Biologie Clinique" (Immuno-analysis and Innovation in Clinical Biology unit, run jointly by Universite Montpellier 1, CNRS, and Sanofi Diagnostics Pasteur) and, since 1999, the "Institut de Biotechnologie et Pharmacologie" (Institute of Biotechnology and Pharmacology, CNRS, Universite Montpellier 1, and BioRad). His pioneering career at the interface between state-funded research and the world of industry also boasts the setting up of a pharmaceutical innovation firm devoted to diabetes treatment (Innodia).
Bernard Pau is the author of 120 international publications and patents in the fields of immunology, biotechnology, and pharmacology. His work and that of his team have led to the industrial development of some fifteen innovative products (bioreagents) including several world firsts.

Rafi Mardachti - Universal Medica Group

Rafi Mardachti is a Pharmacist (Pharm.D) from the University of Paris XI (France). He has an MBA from the Albany College of Pharmacy of Union University (USA). He is a Master of Pharmaceutical Marketing from the University of Paris XI (France). He is the winner of the National Thesis prize in 1995 : Mail Order Pharmacy.

His previous positions were : Regional District Manager at MEDCO (USA), Pharmacist Manager at Marionnaud (France), Health Manager Director at Quintiles (Europe). He is the founder and CEO of Universal Medica.

Rafi Mardachti has published various articles in specialized media and teaches at various schools and specialized Master’s degrees.

Arne SKERRA – XL-protein

Dr. Arne Skerra is Full Professor at the Technische Universitaet Muenchen, where he heads the Institute of Biological Chemistry. He holds a Diplom degree in chemistry from the Technische Universitaet Darmstadt and a PhD in Biochemistry from the Ludwig-Maximilians-Universitaet Muenchen. After post-doctoral studies at the MRC Laboratory of Molecular Biology in Cambridge, UK, and a group leader position at the Max-Planck-Institute for Biophysics in Frankfurt am Main he became Associate Professor for Protein Chemistry at the TU Darmstadt. In 1998 he moved to the TU Munich, where he was appointed to the Chair of Biological Chemistry at the Life Science Campus Weihenstephan. Arne Skerra started his scientific career in the field of protein engineering, where he pioneered, together with Andreas Plueckthun, the biosynthesis of functional antibody fragments in E. coli. Since then, he made several other contributions to this area, including the development of the Strep-tag technology for the purification of recombinant proteins. His main field of research is the design and structural analysis of proteins. One focus is the functional engineering of lipocalin proteins, which laid the basis for the ‘Anticalin’ technology that is commercialized by Pieris AG, a German biotech startup company. Lately, he became also interested in improving the pharmacology of therapeutic proteins, in particular plasma half-life, which led to the development of 'PASylation'. In 2009 he founded the biotech startup company XL-protein GmbH to further exploit this technology.

Pierre-Noël Lirsac – LFB Group

Dr. Pierre-Noël LIRSAC is currently the Director of public Financing and of the cell therapy programs at the LFB group. He got a PhD in biotechnology and started as researcher in radiation biology and joined the French Atomic Energy Commission (CEA) in 1990 as head of laboratory and from 1990 to 2002 as head of the Radiation protection, Biology and Medicine department of the National Institute for Sciences and Nuclear Technologies. In 2002 he joined the Directorate for Enterprises of the French Ministry of Industry as Head of the Biotech and Health Department. From 2004 to end 2006, he ensured the secretariat of the French “Strategic Council for Health Industries” chaired by the Prime Minister. In 2006 he was nominated as Deputy Director for health technologies at CEA. In March 2010 he joined the LFB group.